1. Home
  2. LAW vs NGNE Comparison

LAW vs NGNE Comparison

Compare LAW & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CS Disco Inc.

LAW

CS Disco Inc.

HOLD

Current Price

$8.19

Market Cap

466.2M

Sector

Technology

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$21.15

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAW
NGNE
Founded
2013
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
466.2M
327.8M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
LAW
NGNE
Price
$8.19
$21.15
Analyst Decision
Buy
Strong Buy
Analyst Count
2
6
Target Price
$7.75
$38.50
AVG Volume (30 Days)
283.2K
207.7K
Earning Date
11-05-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$152,677,000.00
N/A
Revenue This Year
$8.51
N/A
Revenue Next Year
$7.46
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.33
N/A
52 Week Low
$3.31
$6.88
52 Week High
$9.11
$37.27

Technical Indicators

Market Signals
Indicator
LAW
NGNE
Relative Strength Index (RSI) 59.57 47.23
Support Level $8.20 $19.03
Resistance Level $8.72 $21.97
Average True Range (ATR) 0.37 1.51
MACD -0.02 0.29
Stochastic Oscillator 57.35 50.24

Price Performance

Historical Comparison
LAW
NGNE

About LAW CS Disco Inc.

CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: